Stem Cells for Fertility: Why Treatment Remains Experimental

Medically reviewed on 2 November 2026 - Dr. Senai Aksoy
Laboratory researcher examining a sample during stem-cell research

Key Takeaways

Stem-cell procedures are being studied when the ovaries stop working before age 40, when IVF drugs produce few eggs, and when the womb lining is damaged or stays thin. Early human studies show a research signal, especially after severe lining damage. They do not prove a standard fertility treatment. The products and methods differ, so routine paid use is not supported.

Key evidence: ISSCR Guidelines for Clinical Translation (2025) Systematic Review of Cellular Therapies for POI and Poor Ovarian Response (2025) Systematic Review of Stem Cells for Thin Endometrium and Asherman Syndrome (2026)

Are stem-cell treatments proven to improve fertility?

No stem-cell intervention is established as a routine fertility treatment. Research has moved beyond laboratory models in a few areas. The evidence is still too limited and uneven to promise more eggs, better embryos, or a higher chance of live birth (a baby born, not only a positive pregnancy test).

The phrase stem-cell treatment can also be misleadingly simple. Studies use different cell sources, manufacturing methods, doses, scaffolds and delivery routes. A result from one product or condition cannot be transferred automatically to another.

The International Society for Stem Cell Research advises that unproven cell-based interventions should remain within well-regulated research and applicable local law. Being offered commercially is not evidence that an intervention works.

What has been studied in the ovary?

Ovarian research mainly concerns primary ovarian insufficiency (POI), poor ovarian response and tissue damage after chemotherapy or radiotherapy. The question is whether a cell-based intervention can improve outcomes that matter to patients, not simply change a laboratory marker.

A 2025 systematic review of human studies — a structured search that gathers all eligible reports — found 27 reports involving 694 participants with POI or poor ovarian response. Almost 78% of the studies had no control group, meaning there was no comparison group that did not receive the cells. The products and injection methods varied widely. Bone-marrow mesenchymal cells were the most common product, and some protocols added platelet-rich plasma (PRP). Pregnancies occurred after treatment, but this evidence cannot show reliably that the cells caused them or identify who might benefit.

Evidence box: ovarian cellular-therapy studies, 2025

The review by Seyihoglu and colleagues included clinical trials, pilot studies and case reports in humans, identified through May 2025. Autologous bone-marrow mesenchymal cells were the most common product: 37% of studies, or 51.8% when protocols that included PRP are counted. Intraovarian injection was the most common route (70.3%). Follow-up of 7–12 months was the most frequent window; the authors noted that this may be too short for safety.

Because most reports had no control group, pregnancies after treatment cannot be attributed to the cells. The authors called for larger trials with standardised cell type, delivery and outcomes.

Changes in AMH (a blood marker of remaining follicles), follicle count or menstrual bleeding are not the same as creating new eggs or reversing age-related chromosome changes. Our guide to how egg numbers relate to IVF outcomes explains why any ovarian marker must be interpreted alongside age, embryo development and previous treatment response.

Clinic offers of an ovarian or uterine injection are also not the same as laboratory research that tries to make eggs from other human cells, sometimes called in vitro gametogenesis. In a 2025 statement, the chair of the UK fertility regulator’s scientific advisory committee called one published study of eggs made from human skin cells a proof of concept. The statement said more work is needed before it could be considered in a clinical setting.

Some laboratory work is even further from patient care. A 2024 mouse study used mouse ovarian cells and mesenchymal stromal cells to construct an artificial ovary model. It helps researchers study tissue interactions; it is not evidence that an ovarian injection restores fertility in humans.

Is the evidence different for the endometrium?

There are early human data for severe intrauterine adhesions, also called Asherman syndrome, and persistently thin endometrium. The signal is worth studying, but it is not yet a routine treatment recommendation.

In a 2025 randomised trial — participants were assigned by chance to cells or a control — researchers enrolled 25 women with refractory thin endometrium related to Asherman syndrome. Live birth occurred in 3 of 11 women analysed in the cell group and 1 of 13 controls. The difference was not statistically significant, meaning it could reasonably be due to chance. The confidence interval — the range of results still compatible with the data — was very wide.

A 2026 systematic review and meta-analysis, which pooled the numbers from those studies, included 18 clinical studies with 323 participants. It reported a thicker lining. In the randomised subset the pooled odds of live birth were higher (odds ratio 2.27, a comparison of odds between groups; the abstract gives a P value of 0.01 but no confidence interval). Products, delivery routes and study designs still differed. The authors concluded that large randomised trials are still needed before this can be recommended as effective endometrial regeneration.

Evidence box: endometrial trials and pooled analyses

In the Hou trial, 25 women were assigned to surgery plus a collagen scaffold with human umbilical-cord mesenchymal cells, or the same scaffold with saline. Results were analysed for 11 and 13 women (24 of the 25). Live birth was 3 of 11 versus 1 of 13 (relative risk 3.55; 95% confidence interval 0.43 to 29.42; P = 0.30). Clinical pregnancy was 5 of 11 versus 1 of 13 (P = 0.06). Two of 11 women in the cell group developed urticaria (hives). Follow-up was one year.

The Adamyan meta-analysis reported a mean endometrial-thickness increase of 2.35 mm (95% CI 1.97 to 2.74). The abstract compares this gain with baseline or control, so it is not purely a controlled comparison. In the randomised subset, the pooled odds ratio for live birth was 2.27 (P = 0.01). No serious adverse events were reported. The authors still stated that large randomised trials are required before the approach can be recommended.

What do the studies not establish?

Current research has clear limits. It has not shown that these interventions create new human eggs or reverse reproductive ageing. It has not shown a reliable gain in embryo quality or live birth for POI or poor ovarian response. It has not shown one standard method that fits both ovarian and uterine disease. Long-term safety for the woman or a future child is not known. These procedures should not replace a usual fertility assessment and treatment plan.

The same caution applies to other regenerative add-ons. Ovarian PRP and exosome-based ovarian interventions are different products with different uncertainties; evidence for one cannot validate another.

What risks and burdens should be discussed?

Risk depends on the cell product and how it is delivered. Possible burdens include infection, bleeding or anaesthetic risk from an invasive procedure; immune reactions; manufacturing or contamination problems; and adverse effects that short follow-up may miss. In the 2025 endometrial trial, two of 11 women who received cells developed hives; that finding cannot be generalised to every product. The ISSCR clinical-translation guidance treats tumour-risk evaluation as part of responsible development. That risk still cannot be generalised across every cell type.

There is also an opportunity cost. Time spent on an unproven intervention may delay an evidence-based plan, which can matter when age or ovarian reserve limits the treatment window. Fees charged outside a credible study can add financial pressure without demonstrating benefit.

How can I assess an offer or a clinical trial?

A registered study is research, not a guarantee of benefit. Before considering participation, ask for clear answers to these questions:

An informed-consent form is important, but it does not replace evidence. The team should explain uncertainty, alternatives and the difference between research objectives and personal clinical benefit.

Dr. Aksoy’s clinical threshold

For Dr. Aksoy, participation is reasonable only as genuine clinical research—not as a paid treatment renamed a trial. The clinical problem must first be confirmed. The international POI guideline defines POI using at least four months of irregular or absent cycles with FSH above 25 IU/L; FSH is repeated after four to six weeks when the diagnosis remains uncertain. For persistent thin endometrium, the finding should recur despite appropriate oestrogen preparation, after evaluating correctable causes such as intrauterine adhesions, a cavity lesion or suspected infection or inflammation.

The protocol should have ethics-committee and regulatory approval, a public registration, and a cell source, manufacturing process and dose that are fully described. Dr. Aksoy would also require GMP manufacturing, independent safety monitoring and long-term follow-up. A phase I study should state plainly when its main purpose is safety. If efficacy is being tested, the outcomes should extend beyond AMH or endometrial thickness to transferable embryos, ongoing pregnancy and live birth.

High charges to the participant, a guarantee of success, absent registration or oversight, or uncertainty about what the product contains are decisive red flags. Research must not consume valuable treatment time either. When follicular activity remains and eggs or embryos may still be obtained in POI, that opportunity should be protected before waiting months for an experimental intervention. When a patient already has embryos and a persistently thin endometrium, correctable causes should be addressed and a clear time limit agreed before a trial delays transfer.

He therefore discusses stem cells neither as a “last chance” nor as a substitute for established care. At most, they are a transparent research option that must not close a better-supported path. This threshold is consistent with the ISSCR clinical-translation principles.

Is routine use supported today?

No. The current evidence supports continued research, not routine commercial fertility treatment. A carefully regulated clinical trial may be reasonable for a narrowly defined group, but that decision depends on the diagnosis, trial quality, remaining established options and the cost of delaying care.

The practical starting point is still a diagnosis-based fertility assessment. Stem-cell research is not a shortcut around ovarian ageing, embryo biology or uterine disease.

Frequently Asked Questions for Dr. Aksoy

Is “stem-cell IVF” an add-on to standard IVF, or a separate treatment? Does it increase live birth?

There is no proven treatment called stem-cell IVF that exists separately from standard IVF. Offers under that name usually involve placing stem cells into the ovary or the lining of the womb, with the aim of improving treatment results. So this is not a method that replaces IVF. These are extra procedures that are still at the research stage.

Some small studies have reported positive findings. Even so, ovarian procedures in particular have not been shown to increase the chance of a live birth. I do not present stem-cell treatment to my patients as an option proven to improve IVF success.

Do you recommend stem cells as a treatment for female infertility?

I do not recommend it as routine care today. Stem cells are being studied in primary ovarian insufficiency, low ovarian reserve and intrauterine adhesions. These should not be treated as one and the same disease.

In women with severe intrauterine adhesions, for example, some results aiming to repair the womb lining are encouraging. By contrast, most studies that try to increase ovarian reserve are small and do not have an adequate control group.

I consider such a treatment appropriate only as part of scientific research, in a centre that has the required ethical and legal approvals. We still do not know enough about whether it works, or about its long-term safety.

Can stem cells increase the chance of pregnancy? Do they really rejuvenate the ovaries?

There are experimental studies suggesting that stem cells might improve the cellular environment and tissue function in the ovaries. Some small human studies have also reported changes in AMH or in follicle count. Those results do not show that the ovaries have truly become younger.

One distinction matters: a rise in AMH does not mean more healthy eggs, or a higher chance of live birth. We have also not shown in humans that stem cells rebuild lost egg reserve, or that they correct age-related chromosomal problems in the eggs.

I do not want to sell my patients hope under the name of ovarian rejuvenation. The research is interesting, and we may develop useful treatments later. Today, however, we cannot say that stem cells reverse ovarian age or reliably increase the chance of pregnancy.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.

Before getting in touch

Please note that certain services, such as sperm donation, egg donation, surrogacy and gender selection (without medical necessity), are not permitted under Turkish law.

We would like to inform you that our clinic strictly adheres to these regulations and does not offer any of these services.

Continue